Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients.

Clinical and molecular hepatology - 1 Jun 2013

Lee Hyun Seok, Kweon Young Oh, Tak Won Young, Park Soo Young, Kang Eun Jung, Lee Yu Lim, Yang Hae Min, Park Hyun Woo

Abstract excerpt

BACKGROUND/AIMS: Chronic hepatitis C patients with advanced fibrosis have unsatisfactory sustained virological response (SVR) rates. Few data demonstrating the efficacy of combination therapy in chronic hepatitis C patients with advanced fibrosis in South Korea are available. The purpose of this study was to assess whether the stage of fibrosis impacts the efficacy of combination therapy for chronic hepatitis C....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Platelets
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Liver Cirrhosis

Share to Multivariate Analysis

Share to Polyethylene Glycols

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 23837139
DOI: 10.3350/cmh.2013.19.2.148
PMCID: PMC3701847

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients.PMID 23837139Read ↗

Incidentally detected asymptomatic hepatitis C virus infection with significant fibrosis: Possible impacts on management.Semantic proximity Read ↗

Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?Semantic proximity Read ↗

Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease.Semantic proximity Read ↗

Factors associated with severity and disease progression in chronic hepatitis C.Semantic proximity Read ↗

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.Semantic proximity Read ↗

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.Semantic proximity Read ↗

Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.Semantic proximity Read ↗

Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C in Brazil.Semantic proximity Read ↗

Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study.Semantic proximity Read ↗

Older age at the time of liver biopsy is the important risk factor for advanced fibrosis in patients with chronic hepatitis C.Semantic proximity Read ↗

Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B.Semantic proximity Read ↗

Predictors of histological activity and fibrosis in chronic Hepatitis C infection: a study from North India.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.